Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.
Clinical trials of human epidermal growth factor receptor 2 (HER2)-targeted agents added to standard treatment have been efficacious for HER2-positive (HER2+) advanced breast cancer. To our knowledge, no meta-analysis has evaluated HER2-targeted therapy including trastuzumab emtansine (T-DM1) and pe...
Main Authors: | Qiuyan Yu, Zhenli Zhu, Yan Liu, Jun Zhang, Ke Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4439018?pdf=render |
Similar Items
-
Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
by: Xiaohui Zhang, et al.
Published: (2021-08-01) -
HER-2/neu overexpression in breast cancer
by: Rana S. Aziz, et al.
Published: (2010-10-01) -
Lapatinib for HER2 overexpressing breast cancer
by: Jones, Jeremy, et al.
Published: (2009) -
HER2-Targeted Multifunctional Silica Nanoparticles Specifically Enhance the Radiosensitivity of HER2-Overexpressing Breast Cancer Cells
by: Haruka Yamaguchi, et al.
Published: (2018-03-01) -
Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
by: Shanshan Chen, et al.
Published: (2019-10-01)